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Summary: Although endometrial carcinoma (EC) is generally considered to have a good
prognosis, over 20% of women with EC die of their disease, with a projected increase in
both incidence and mortality over the next few decades. The aim of accurate
prognostication is to ensure that patients receive optimal treatment and are neither
overtreated nor undertreated, thereby improving patient outcomes overall. Patients with
EC can be categorized into prognostic risk groups based on clinicopathologic ﬁndings.
Other than tumor type and grade, groupings and recommended management algorithms
may take into account age, body mass index, stage, and presence of lymphovascular
space invasion. The molecular classiﬁcation of EC that has emerged from the Cancer
Genome Atlas (TCGA) study provides additional, potentially superior, prognostic
information to traditional histologic typing and grading. This classiﬁer does not,
however, replace clinicopathologic risk assessment based on parameters other than
histotype and grade. It is envisaged that molecular and clinicopathologic prognostic
grouping systems will work better together than either alone. Thus, while tumor typing
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and grading may be superseded by a classiﬁcation based on underlying genomic
abnormalities, accurate assessment of other pathologic parameters will continue to be
key to patient management. These include those factors related to staging, such as depth
of myometrial invasion, cervical, vaginal, serosal surface, adnexal and parametrial
invasion, and those independent of stage such as lymphovascular space invasion. Other
prognostic parameters will also be discussed. These recommendations were developed
from the International Society of Gynecological Pathologists Endometrial Carcinoma
project. Key Words: Endometrial carcinoma—Prognosis—Pathology—Myometrium
invasion—MELF—Cervical stromal invasion—Lymphovascular space invasion—
Adnexal involvement—Staging.
Endometrial carcinoma (EC) is generally considered
to be associated with a good prognosis, largely because
low-grade endometrioid carcinoma is the most common
subtype and is typically low stage at clinical presenta-
tion. However, over 20% of women with EC die of their
disease, and there is a projected increase in both
incidence and mortality over the next few decades. The
aim of accurate and reproducible prognostication is to
ensure that patients receive optimal treatment and are
neither overtreated nor undertreated, thereby improv-
ing patient outcomes overall.
Histologic parameters that need to be recorded in
hysterectomy specimens according to the recommenda-
tions of the National Comprehensive Cancer Network are
listed in Table 1 (1). Other than tumor type and grade,
prognostic risk groupings and recommended management
algorithms take into account stage, as well as age, ﬁtness
for surgical treatment, fertility-conservation, presence of
lymphovascular space invasion (LVSI), and other factors.
Recommendations show minor variation in different
jurisdictions and Tables 2–5 list the most widely followed
National Comprehensive Cancer Network and European
Society forMedical Oncology presurgical and postsurgical
recommendations; it should be noted that the latter, that is
recommendations for adjuvant treatment, are made
almost entirely on the basis of pathologic ﬁndings (1–3).
The molecular classiﬁcation of EC that has emerged
from the Cancer Genome Atlas (TCGA) study provides
additional potentially superior prognostic information
to traditional histologic typing and grading. This
classiﬁer does not, however, replace clinicopathologic
risk assessment based on parameters other than
histotype and grade (4–6). It is envisaged that molecular
and clinicopathologic prognostic grouping systems will
likely work better together. Thus, while tumor typing
and grading may be partly or totally superseded by a
classiﬁcation based on underlying genomic abnormal-
ities, accurate assessment of pathologic parameters
other than tumor morphology will continue to be key
to patient management. Lack of agreement in the
assessment of these parameters is well documented in
the literature (7–12) and this article focuses on ways to
minimize disagreement and promote uniformity in the
approach to their recognition. These include those
factors that are related to staging (13,14) (Table 6), and
those independent of stage.
These recommendations were developed from the
International Society of Gynecological Pathologists
Endometrial Carcinoma project.
TABLE 1. Pathologic assessment to be included in
evaluation of hysterectomy specimens (1)
Uterus
Ratio of depth of myometrial/stromal invasion to myometrial
thickness
Cervical involvement (including depth of stromal invasion)
Tumor size
Tumor location (fundus vs. lower uterine segment/cervix)
Histologic subtype with grade
Lymphovascular space invasion
Fallopian tubes/ovaries
Peritoneal cytology*
Nodes (when resected)
Level of nodal involvement (i.e. pelvic, common iliac, paraaortic)
Size of metastasis (isolated tumor cells, micrometastasis,
macrometastasis)
Universal testing of endometrial cancers for mismatch repair
(MMR) gene
Testing should be done on the ﬁnal hysterectomy specimen (can
be done on presurgical biopsy if hysterectomy not performed)
MLH1 loss should be further evaluated for promoter methylation
to assess epigenetic process
Genetic counseling and testing for all other MMR abnormalities
For those who are dMMR-negative or those who have not been
screened, but who have a strong family history of endometrial
and/or colorectal cancer, genetic counseling and testing for
patients is recommended
Estrogen receptor testing in setting of stages III, IV, and recurrent
disease
*Although cytology by itself does not affect FIGO staging,
cytology results should still be obtained because positive cytology is
an adverse risk factor.
Adapted with permission from National Comprehensive Cancer
Network.
dMMR indicates mismatch repair deﬁcient; FIGO, International
Federation of Gynecology and Obstetrics.
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PATHOLOGIC PROGNOSTIC FACTORS
Tumor Stage
Recommendations:
 Provisional pathologic staging should be provided in
the pathology report for all hysterectomy specimens
from cases of EC.
 The TNM staging system (Union for International
Cancer Control and American Joint Committee on
Cancer versions) for EC is largely concordant with the
widely used International Federation of Gynecology
and Obstetrics (FIGO) system (Table 6) (15).
Regardless of the system used, staging remains the
most powerful prognostic indicator in EC and depends
on accurate assessment of a range of pathologic factors
that are individually considered below.
 Pathologic reporting guidelines worldwide (16)
recommend that tumor stage should be provided in
TABLE 2. NCCN endometrial cancer primary treatment algorithms (1)
Initial clinic ﬁndings
Additional workup/ﬁndings
on additional workup Primary treatment
Disease limited to the uterus
(endometrioid histology)
Medically operable TH/BSO and surgical staging*†‡
Patient desires fertility-sparing option§ Continuous progestin-based therapy:
Megestrol
Medroxyprogesterone acetate
Levonorgestrel intrauterine device
Surveillance as below∥
Not suitable for primary surgery EBRT and/or brachytherapy (preferred) OR consider
systemic therapy in selected patients
Suspected or gross cervical involvement
(endometrioid histology)
Cervical biopsy or pelvic MRI (if not
previously done): negative result
TH/BSO and surgical staging*†‡
Cervical biopsy or pelvic MRI (if not
previously done): positive result;
medically operable
TH/BSO and surgical staging*† OR EBRT+
brachytherapy followed by TH/BSO and surgical
staging*†
Cervical biopsy or pelvic MRI (if not
previously done): positive result; not
suitable for primary surgery
EBRT+brachytherapy followed by surgical resection if
rendered operable OR systemic therapy followed by
surgical resection if rendered operable (EBRT+
brachytherapy if still inoperable)
Suspected extrauterine disease
(endometrioid histology)
CA125 (optional); imaging as clinically
indicated (if not previously done): no
evidence of extrauterine disease
As above for disease limited to the uterus
CA125 (optional); imaging as clinically
indicated (if not previously done):
ascites; omental/peritoneal involvement;
nodal (including inguinal) involvement;
ovarian involvement
TH/BSO+surgical staging/debulking (consider
preoperative chemotherapy
Initially unresectable extrauterine pelvic
disease: vaginal; bladder; bowel/rectum;
parametrial; nodal
EBRT +/− brachytherapy +/− systemic therapy
followed by reevaluation for surgical resection OR
systemic therapy followed by reevaluation for
surgical resection and/or RT based on response
Distant visceral metastasis Systemic therapy and/or EBRT and/or hormonal
therapy AND consider TH/BSO
Biopsy ﬁndings: serous carcinoma or
clear-cell carcinoma or undifferentiated/
dedifferentiated carcinoma or
carcinosarcoma
CA125 (optional); imaging: no
extrauterine disease
TH/BSO and surgical staging
Extrauterine disease Consider maximal tumor debulking for gross disease
*Minimally invasive surgery (MIS) is the preferred approach when technically feasible.
†The degree of surgical staging to assess disease status depends on preoperative and intraoperative ﬁndings.Multidisciplinary expertise is recommended.
‡Ovarian preservation may be safe in select premenopausal women with early-stage endometrial cancer.
§Criteria for considering fertility-sparing options for management of endometrial carcinoma (all criteria must be met): well-differentiated
(grade 1) endometrioid carcinoma on dilatation and curettage (D&C) conﬁrmed by expert pathology review. Disease limited to the
endometrium on MRI (preferred) or transvaginal ultrasound. Absence of suspicious or metastatic disease on imaging. No contraindications to
medical therapy or pregnancy. Patients should undergo counseling that fertility-sparing option is NOT standard of care for the treatment of
endometrial carcinoma. Consultation with a fertility expert before therapy. Genetic counseling/testing in selected patients (see table 1).
∥Surveillance through endometrial sampling every 3 to 6mo (either D&C or endometrial biopsy): Complete response by 6mo: Encourage
conception (with continued surveillance every 3–6mo). TH/BSO with staging after child-bearing complete or progression of disease on
endometrial sampling. Endometrial cancer present at 6 to 12mo: TH/BSO with staging.
Adapted with permission from National Comprehensive Cancer Network.
EBRT indicates external beam radiotherapy; MRI, magnetic resonance imaging; NCCN, National Comprehensive Cancer Network; TH/
BSO, total hysterectomy and bilateral salpingo-oophorectomy.
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the pathology report as FIGO stage, and in some
jurisdictions TNM staging is also mandated, specifying
the version used. The International Collaboration on
Cancer Reporting (ICCR) and Royal College of
Pathologists (UK) (RCPath) datasets stress that
staging in the pathology report is provisional as the
ﬁnal stage should be determined when all relevant
clinical and radiologic information is available to be
integrated with the pathologic ﬁndings.
 Some locations of tumor spread are not speciﬁcally
addressed in the FIGO staging system. A few that are
listed below have been conﬁrmed by the TNMhelpdesk
(Dr Lynn Hirschowitz, personal communication,
written form):
 Spread to pelvic serosa including bladder,
sigmoid serosa and cul de sac is staged as
FIGO IIIA.
 Spread to serosa in the abdominal cavity
(abdominal peritoneal involvement) is staged as
FIGO IVB (pM1).
 Spread to omentum (supracolic or infracolic) is
staged as FIGO IVB (pM1).
It should be noted that, for the purposes of staging
gynecologic cancers, pelvic peritoneum (and organs
within pelvis) are within the “true pelvis,” and
abdominal peritoneum and related organs are outside
the conﬁnes of the true pelvis. The true pelvis, also
known as the lesser pelvis, is below the level of the
pelvic brim, between the pelvic inlet and the pelvic
ﬂoor (17). The true pelvis contains the sigmoid colon,
rectum, and bladder, as well as all gynecologic organs.
Myometrial Invasion
Recommendations:
 Absence or presence and depth of myometrial
invasion should be reported in all EC as “none or
less than half” OR “half or more.”
TABLE 3. ESMO endometrial cancer surgical management algorithms based on preoperative assessment* (1,2)
Clinical stage Risk group Surgery Lymphadenectomy†
Clinical stage I Low risk: clinical stage IA, G1/2,
endometrioid type
Total hysterectomy and bilateral salpingo-
oophorectomy without vaginal cuff‡§
Not recommended
Intermediate risk:
clinical stage IA, G3,
endometrioid type
clinical stage IB, G1/2,
endometrioid type
Total hysterectomy and bilateral salpingo-
oophorectomy without vaginal cuff
Can be considered for staging.
SLND is an option
High risk:
clinical stage IB, G3,
endometrioid type
all stages with nonendometrioid type
Total hysterectomy and bilateral salpingo-
oophorectomy without vaginal cuff
Recommended
Clinical stage II Total hysterectomy and bilateral salpingo-
oophorectomy; modiﬁed (type B) or type
A radical hysterectomy to be considered if
required for obtaining free margins
Recommended to guide
staging and adjuvant
therapy
Clinical stages
III–IV
Good PS: where feasible, complete macroscopic
cytoreduction (including resection of metastases)
Impaired PS or unresectable disease: multimodality
treatment to be considered (including cases when
surgery may signiﬁcantly impair vaginal function)
Recommended as part of
comprehensive staging
*Mandatory and additional assessments as below: mandatory assessments: family history, chest x-ray (when abdominal CT is performed,
thoracic assessment can replace chest x-ray), clinical and gynecologic assessment (including inventory of comorbidities, and geriatric
assessment, if appropriate), transvaginal ultrasound, complete pathology assessment (histotype and grade) by endometrial biopsy/curettage +/−
hysteroscopy if needed. Additional assessments: abdominal CT (to investigate extrapelvic disease), contrast enhanced MRI (to assess cervical
involvement and/or myometrial invasion in apparent stage I EC (MRI to assess myometrial invasion in apparent stage I EC should only be
undertaken in institutions where the indication for LND is tailored according to risk groups).
†Lymphadenectomy to include systematic removal of pelvic and paraaortic nodes up to the level of the renal veins.
‡Ovarian preservation can be considered in women <45-yr old with <50% myometrial invasion, no obvious extrauterine disease and no
family history of ovarian cancer risk.
§Patients with AH/EIN or G1 EEC requesting fertility-preserving therapy must: be referred to specialized centers; undergo D&C with or without
hysteroscopy; have AH/EIN or G1 EEC conﬁrmed by a specialist gynecologic pathologist; undergo pelvic MRI to exclude overt myometrial
invasion and adnexal involvement; be fully informed that fertility-sparing treatment is a nonstandard treatment; be willing to accept close follow-up.
For patient undergoing fertility-preserving therapy, medroxyprogesterone acetate (MPA) or megestrol acetate (MA) is recommended; progestin-
loaded IUD is also an option. After completion of child-bearing, hysterectomy, and salpingo-oophorectomy is recommended.
CT indicates computed tomography; ESMO, European Society for Medical Oncology; MRI, magnetic resonance imaging; SLND, sentinel
lymph node dissection.
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TABLE 4. NCCN adjuvant therapy determinations for endometrial carcinoma based on pathologic ﬁndings (1)
Surgical staging (histology) Pathologic stage* Pathologic ﬁndings Adjuvant treatment†
Surgically staged
(endometrioid histology)
Stage IA (o50% myometrial
invasion)
Adverse risk factors‡
not present
Grade 1 Observe
Grade 2 Observe or vaginal brachytherapy
Grade 3 Observe or vaginal brachytherapy
Adverse risk factors‡
present
Grade 1 Observe or vaginal brachytherapy
Grade 2 Observe or vaginal brachytherapy and/or EBRT§
Grade 3 Vaginal brachytherapy and/or EBRT +/− systemic
therapy§
Stage IB (≥ 50% myometrial
invasion)
Adverse risk factors‡
not present
Grade 1 Observe or vaginal brachytherapy
Grade 2 Observe or vaginal brachytherapy
Grade 3 Vaginal brachytherapy and/or EBRT +/− systemic
therapy§
Adverse risk factors‡
present
Grade 1 Observe or vaginal brachytherapy and/or EBRT
Grade 2 Observe or vaginal brachytherapy and/or EBRT
Grade 3 EBRT and/or vaginal brachytherapy +/− systemic
therapy∥
Stage II¶#** See note# Grade 1 Vaginal brachytherapy and/or EBRT
Grade 2 Vaginal brachytherapy and/or EBRT
Grade 3 EBRT and/or vaginal brachytherapy +/− systemic
therapy∥
Stages III, IV†† Stage IIIA Systemic therapy and/or EBRT +/− vaginal
brachytherapy
Stage IIIB Systemic therapy and/or EBRT +/− vaginal
brachytherapy
Stage IIIC1 (pelvic node positive) Systemic therapy and/or EBRT +/− vaginal
brachytherapy
Stage IIIC2 (paraaortic node
positive +/− pelvic node positive)
Systemic therapy and/or EBRT +/− vaginal
brachytherapy
Stages IVA, IVB Systemic therapy and/or EBRT +/− vaginal
brachytherapy
Incompletely surgically staged
(endometrioid histology)
Intrauterine Stage IA, G1-2 (o50% myometrial invasion, no LVSI,
and <2 cm tumor
Observe
Intrauterine Stage IA, G1-2 (o50%
myometrial invasion) with LVSI,
or ≥ 2 cm tumor, Stage IA G3,
Stage IB, Stage II
Imaging negative As above
Imaging suspicious/positive Surgically restage or pathologic conﬁrmation of
metastatic disease in select patients
Then management as above
Surgical restaging Then management as above
High-risk carcinoma
histologies:
Serous carcinoma
Clear-cell carcinoma
Undifferentiated/
dedifferentiated carcinoma
Carcinosarcoma
Stage IA Observe‡‡ OR chemotherapy +/− vaginal
brachytherapy (preferred) OR EBRT +/−
vaginal brachytherapy
Stages IB, II, III, IV Chemotherapy +/− EBRT +/− vaginal
brachytherapy
*The degree of surgical staging to assess disease status depends on preoperative and intraoperative ﬁndings. Multidisciplinary expertise is
recommended.
†Adjuvant therapy recommendations are made on the basis of pathologic ﬁndings.
‡Potential adverse risk factors include the following: age, positive lymphovascular invasion, tumor size, and lower uterine segment or surface
cervical glandular involvement.
§Level of recommendation: category 2B (all recommendations are category 2A unless otherwise indicated).
∥The role of adjuvant chemotherapy in invasive high-grade, uterus-conﬁned disease is the subject of current studies. Hormonal therapy is not
used for high-grade disease.
¶Consider additional imaging if not previously done.
#Observation or vaginal brachytherapy is also an option for patients with stage II disease who have had a radical hysterectomy with negative
surgical margins and no evidence of extrauterine disease.
**The adverse fundal risk factors inﬂuencing therapy decisions for stage I disease‡may also impact the choice of adjuvant therapy for stage II disease.
††Additional imaging if not previously done.
‡‡Observation only for select patients with no residual serous or clear-cell carcinoma in the hysterectomy specimen.
Adapted with permission from National Comprehensive Cancer Network.
EBRT indicates external beam radiotherapy; LVSI, lymphovascular space invasion; NCCN, National Comprehensive Cancer Network.
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 Percentage invasion or measurements of depth
and total myometrial thickness from which the
above can be derived are acceptable alternatives.
 If myometrial invasion occurs from carcinoma
within adenomyosis, the deepest myoinvasive point
should be reported according to where this is
located in the myometrium, and regardless of
whether or not it arises from adenomyosis.
 In low-grade endometrioid EC where invasion
arising from adenomyotic foci in the outer half
of the myometrium is the only focus of invasion
in the outer half, this should be noted and
accompanied by a comment that the clinical
signiﬁcance is unknown, and that this may be
an overestimate of true depth of invasion. In
other words, in the absence of tumor extension
to other organs, the tumor should be staged as
FIGO IB, with a proviso that it could be an
overestimation of the actual depth of invasion.
 In case of an exophytic tumor, the depth of
myometrial invasion, and not tumor thickness,
should be measured by identifying the adjacent
endomyometrial junction and by correlating with
the macroscopic appearance.
 For tumors involving polyps, measurement of
invasion is performed only if the tumor invades
the underlying myometrium and measurement
should be performed from the adjacent endome-
trial-myometrial interface. Invasion into polyp
TABLE 5. ESMO endometrial cancer adjuvant treatment algorithm based on ﬁnal histotype
and postsurgical staging according to FIGO 2009 system (1,2)
Risk group Nodal status Adjuvant treatment
Low risk EEC: Stage I grades 1–2, <50%
myometrial invasion, LVSI negative
NA No adjuvant treatment
Intermediate risk EEC: Stage I, grades 1–2,
≥ 50% myometrial invasion,
LVSI negative
NA Adjuvant brachytherapy
No adjuvant therapy is an option, especially
for patients <60-yr old
High-intermediate risk EEC:
Stage I, grade 3, <50% myometrial invasion,
regardless of LVSI status
Stage I, grades 1–2, LVSI unequivocally
positive; regardless of depth
of myometrial invasion
Surgical nodal staging
performed, node
negative
Adjuvant brachytherapy
No adjuvant therapy is an option
No surgical nodal staging
performed
Adjuvant brachytherapy for G3 and LVSI negative
Adjuvant EBRT for LVSI unequivocally positive
High-risk EEC: Stage I,
grade 3, ≥ 50% myometrial invasion,
regardless of LVSI status
Surgical nodal staging
performed, node
negative
Adjuvant EBRT with limited ﬁelds
Adjuvant brachytherapy is an alternative option
No surgical nodal staging
performed
Adjuvant EBRT
Adjuvant chemotherapy (combined and/or sequential)
can be considered (greater evidence to support
combined chemotherapy plus EBRT than either
individual modality alone)
High-risk EEC: Stage II Surgical nodal staging
performed, node
negative
Adjuvant vaginal brachytherapy for G1-2 LVSI negative
Adjuvant limited ﬁeld EBRT for G3 or LVSI
unequivocally positive; consider brachytherapy boost
No surgical nodal staging
performed
Adjuvant EBRT, consider brachytherapy boost
Adjuvant chemotherapy for G3 or LVSI unequivocally
positive (combined and/or sequential) should be considered
High-risk EEC: Stage III, no residual disease Chemotherapy plus EBRT to be considered for IIIA,
IIIB and IIIC1
Chemotherapy plus enhanced ﬁeld EBRT to be
considered for IIIC2
High risk, nonendometrioid cancer
(serous or clear-cell or undifferentiated
carcinoma or carcinosarcoma)
Serous and clear cell after comprehensive staging:
Chemotherapy (clinical trials encouraged)
Stage IA, LVSI negative: Vaginal brachytherapy
Stage ≥ IB: EBRT plus chemotherapy especially
if node positive
Carcinosarcoma and undifferentiated tumors:
Chemotherapy
Consider EBRT (clinical trials encouraged)
EBRT indicates external beam radiotherapy; EEC, endometrioid endometrial carcinoma; ESMO, European Society for Medical Oncology;
FIGO, International Federation of Gynecology and Obstetrics; LVSI, lymphovascular space invasion; NA, not applicable.
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stroma can be described, but its depth should not
be measured.
 The depth of myometrial invasion of tumors within
the lower uterine segment should be measured as
elsewhere in the uterine corpus; that is, as “none or
less than half” OR “half or more” of myometrial
thickness at that location.
 When EC invades a leiomyoma, the thickness of
the myometrial wall at this site should be measured
to include the leiomyoma and this distance should
be used in calculating the depth of invasion.
 In EC with a microcystic, elongated and frag-
mented (MELF) pattern of invasion, the presence
of desmoplasia alone is insufﬁcient to measure
depth of invasion. Levels and cytokeratin stains
may be examined if necessary to identify malignant
cells within these areas and measurement of deepest
invasion should take into account the deepest area
where these are seen.
 LVSI should not be included in assessment of
myoinvasive depth; only carcinoma inﬁltrating the
myometrium is included in this measurement.
Depth of myometrial invasion has consistently been
found to be an independent predictor of both lymph
node (LN) metastasis and overall prognosis in EC.
For this reason, depth of invasion has been a
component of the FIGO staging system for EC for
over 2 decades. However, depth of myometrial
invasion is not always easy to assess as the endome-
trium has an irregular interface with the underlying
myometrium and it is reported that pathologists
disagree on myoinvasive depth in about 30% of cases
(11). Measurement of myoinvasion is performed only
if the tumor invades the myometrium in relation to
the endometrial-myometrial interface. The demarca-
tion zone is the midpoint of an axis drawn from the
external surface of the uterus to the junction of the
closest non-neoplastic endometrial lining and under-
lying myometrium. Depth of myometrial invasion is
assessed as the deepest point of invasion relative to the
demarcation zone, and expressed as “less than half”
or “half or more.” When the junction is completely
obliterated, or there is no junction from which to
measure, the vascular arcuate plexus can be used to
assess myoinvasive depth; invasion well into or
through the plexus usually signiﬁes > 50% myoinva-
sion; however, if inﬁltration barely extends into the
plexus, the depth of invasion should be calculated
with reference to the thickness of the myometrium in
the opposite uterine wall (11,18). It should be noted
that LVSI is not included in assessment of myoinva-
sive depth; only carcinoma inﬁltrating the myome-
trium is included in this measurement.
In some instances, assessment of depth of myome-
trial invasion can be particularly challenging, such as
with exophytic tumors, or those involving polyps, or
in areas where the myometrium is thin such as in the
uterine cornua or isthmus, or when invasion emanates
from adenomyosis or involves a leiomyoma. A further
TABLE 6. FIGO and TNM staging systems of endometrial carcinoma
Site Extent TNM group FIGO stage
Primary tumor cannot be assessed NA Tx NA
No evidence of primary tumor NA T0 NA
Stage I: tumor conﬁned to uterus Carcinoma in situ (preinvasive carcinoma) Tis IA
No or <50% myometrial invasion T1a IA
≥ 50% myometrial invasion T1b IB
Stage II: tumor invades stromal connective tissue of the
cervix but does not extend beyond the uterus
Tumor involves the uterus and the cervical stroma T2 II
Stage III: tumor extends beyond uterus without distant
metastasis
Tumor involves serosa or adnexa (direct extension
or metastases)
T3a IIIA
Vaginal and/or parametrial involvement
(direct extension or metastases)
T3b IIIB
Stage III: lymph node metastasis Pelvic lymph node involvement N1 IIIC1
Paraaortic lymph node involvement, with or
without pelvic node involvement
N2 IIIC2
Stage IV: bladder/bowel mucosa or distant spread Tumor invades bladder mucosa and/or bowel
mucosa
T4 IVA
Distant metastases including abdominal metastases
and/or inguinal lymph nodes
M1 IVB
Positive peritoneal cytology has to be reported without altering stage.
TNM stage grouping: Stage IA: T1aN0M0; Stage IB: T1bN0M0; Stage II: T2N0M0; Stage IIIA: T3aN0M0; Stage IIIB: T3bN0M0; Stage
IIIC1: T1/T2/T3N1M0; Stage IIIC2: T1/T2/T3N2M0; Stage IVA: T4N0-2M0; Stage IVB: T1-4N0-2M1.
FIGO indicates International Federation of Gynecology and Obstetrics; NA, not applicable.
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challenge is whether or not to include desmoplasia
without evident neoplastic cells in tumors showing a
MELF pattern of invasion.
Tumors With an Exophytic Growth or Involving Polyps
In the ﬁrst scenario, it is important to note that
exophytic tumors often incorporate smooth muscle
within their core and this should not be misinterpreted
as myometrial invasion. Thus, depth of invasion but
not tumor thickness should be measured by identify-
ing the adjacent endomyometrial junction and corre-
lating the ﬁndings with the macroscopic location of
the tumor (11). Similarly, for tumors involving polyps,
invasion into the polyp stroma may occur but this
does not represent myometrial invasion. Measure-
ment of myoinvasion is performed only if the tumor
invades the myometrium in relation to the endome-
trial-myometrial interface. Correlation with gross
ﬁndings is useful, as well as taking relevant sections
from elsewhere in the uterine wall, that is, not only
those sections that represent the tumor either in its
exophytic areas or within the polyp.
Myometrial Invasion From a Focus of Adenomyosis
Several studies have shown that ECs conﬁned to
foci of adenomyosis have a prognosis that is similar to
those conﬁned to the endometrium; involvement
conﬁned to adenomyotic foci should therefore not
be misinterpreted as evidence of myometrial invasion.
Rarely, there may be myometrial invasion only at a
site where tumor involves adenomyosis. There are
2 possible ways to address depth of invasion in this
scenario:
(1) Assess the deepest point of invasion based on
where it is located in the myometrium regardless
of whether or not it from adenomyosis, in relation
to the myometrial thickness as assessed above (19).
(2) Measure from the edge of the adenomyotic focus
to the furthest point of invasion (20), and express
this as a fraction of myometrial thickness.
In deciding which of these 2 approaches to
recommend, we reviewed the impact of the presence
of adenomyosis on prognosis in patients with EC, as
there are no data directly comparing these 2 methods
of assessing depth of invasion associated with
adenomyosis to determine which is more prognosti-
cally discriminatory. In some studies, the presence of
adenomyosis in low-grade endometrioid carcinoma
has no impact on prognosis (21,22) while some regard
it as a marker of less aggressive disease (23,24). In
other studies, the presence of adenomyosis is asso-
ciated with a higher incidence of myometrial invasion,
likely due to increase in tumor interface surface area
with the adjacent myometrium, as well as a slightly
increased likelihood of deeper myometrial invasion;
however, this ﬁnding does not appear to impact on
overall prognosis as typically foci of invasion appear
to be small when compared with deeply invasive EC
without associated adenomyosis (22,25–27).
In the absence of randomized trial data with direct
comparison of outcomes based on these 2 methods of
assessment of depth of invasion of tumor arising from
adenomyosis, the group felt it to be preferable to adhere
to standard and reproducible protocols. Of the 2
approaches listed, the ﬁrst is more likely to be
reproducible and less error-prone, whereas the second
approach presents a possible danger of understaging an
EC with deep myoinvasion. In the latter setting,
interobserver variability can be anticipated given the
absence of established measurement criteria. Further-
more, accurate measurement of depth of invasion may
be difﬁcult as the orientation of the adenomyotic foci
may differ from the normal endomyometrial plane.
Thus, it is preferable to use the standard method for
determining depth of invasion, based on the location of
the deepest focus of invasive carcinoma in relation to
the total myometrial thickness in this area, irrespective of
its relationship to adenomyosis (Fig. 1). In cases where
the EC appears to be directly invading from
adenomyosis, this ﬁnding should be commented on in
the report, as it may be associated with less aggressive
behavior than that of tumors with conventional invasion
at a similar depth. It is acknowledged by the authors that
this is an area that requires further research.
Myometrial Invasion in Cornual or Lower Uterine
Segment/Isthmic (LUS) Locations
Literature is scant in providing guidelines to
measure depth of invasion for tumors located in the
LUS or cornua. It is important to note that these
regions have a much thinner myometrium. The LUS
is easy to identify from sections that contain the
inactive or ciliated glands and ﬁbrous stroma charac-
teristic of this location or also contain upper
endocervix or from the section code but location in
the cornu may be overlooked when grossing. In
general, it is agreed that depth of invasion should be
measured as elsewhere in the uterine corpus but it is
recommended that sections from the cornual region
should not be used to determine myoinvasive depth
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unless the tumor is located wholly in this region or it
reaches/breaches the serosa only in this region (28).
Tumors With MELF Pattern of Invasion
A MELF pattern of myometrial invasion may be
associated in the deepest areas with a desmoplastic
response or inﬂammatory reaction which should not
be counted as the deepest point of invasion if no
associated malignant cells are identiﬁed. Especially in
inﬂammatory areas, malignant cells may be difﬁcult
to appreciate as they can display a histiocytoid
morphology with very innocuous cytologic features
that may result in misinterpretation as true histiocytes
(Fig. 2). In either scenario, if malignant cells are not
seen, levels and/or cytokeratin staining can be
performed, though the latter are not generally
recommended, or extra sections may be taken to
determine myoinvasive depth (29–32).
Cervical Involvement
Recommendations:
 Presence or absence of cervical stromal invasion must
be recorded as its presence upstages an EC to stage II.
 Recognition of cervical stromal invasion may
be facilitated by the ﬁnding of a desmoplastic/
inﬂammatory reaction but may occur in its absence.
In the latter situation, recognition is facilitated by
the observation of altered architecture relative to
normal endocervical crypts.
 For the purposes of standard reporting, the uppermost
endocervical mucinous gland identiﬁed in the section
should be taken as the upper limit of the endocervix.
 In the presence of cervical stromal invasion, the
status of radial and distal margins (including
minimum distance) should be included as well as
depth of invasion within the cervical stroma.
 Cervical epithelial involvement is no longer part of
FIGO staging for EC; however, it is recommended
that this ﬁnding should be included in the report.
Historically, cervical involvement has been considered
important for prognostication in patients with EC.
However, since 2009, involvement limited to cervical
epithelium is no longer considered as FIGO stage II
(previously as IIA) as it has been shown that patients
with cervical epithelial involvement have identical out-
comes to those with stage I tumors. However, this is still
included as a potential adverse risk factor for consid-
eration of adjuvant therapy (1). As patients with EC
associated with cervical stromal invasion have a worse
prognosis (see below), this is categorized as FIGO stage
II with a recommendation for adjuvant treatment (2).
Patients with tumors showing cervical involvement
are considered to have a worse prognosis (overall
survival) that those with tumors conﬁned to the
corpus. However, such patients generally have other
FIG. 1. If myometrial invasion occurs from carcinoma within
adenomyosis, the distance of the deepest myoinvasive point from
the outer surface of the myometrium (short solid arrow) should be
measured in relation to the myometrial thickness (long solid arrow),
rather than the distance of the invasive depth of the focus (dashed
arrow) taken as the extent of myoinvasion. Courtesy of Lucas
Catalan Galan and Laura Casey.
FIG. 2. Infiltrative glands in foci showing a microcystic, elongated,
and fragmented pattern may be difficult to appreciate, as the lining
is attenuated and individual tumor cells may have a histiocytoid
appearance.
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known poor prognostic factors such as high tumor
grade, deep myometrial invasion, and LVSI (33,34).
When matched for other prognostic factors (cell type,
grade, depth of myometrial invasion, LVSI, age, and
nodal involvement), cervical involvement, including
depth of cervical stromal invasion was not a
signiﬁcant prognosticator by univariate or multi-
variate analysis in a large study of 200 ECs (35). In
another study, distinction between stages IIA and IIB
(prior FIGO staging system) or depth of stromal
invasion did not affect survival in patients with
endometrioid EC. Only age, LVSI, and type of
treatment were predictors of survival in patients with
stage II endometrioid EC (36).
Cervical stromal invasion has also been correlated
with recurrence in patients with EC. In 1 study, within
the category of low-grade endometrioid ECs, univariate
analysis showed cervical stromal involvement along
with large tumor size, deep myoinvasion, MELF pattern
of invasion, tumor necrosis, LVSI, and pelvic/paraaortic
LN metastasis to be more common in patients whose
tumors recurred at extravaginal sites (37).
Besides controversies regarding the prognostic
signiﬁcance of cervical involvement, including stromal
invasion, reproducibility/accuracy in determining the
presence and type of involvement has been shown to
be low among pathologists (7,12,35). This diagnostic
performance is related to a variety of morphologic
issues that complicate the interpretation of cervical
involvement in EC and which need to be addressed in
order to standardize criteria, and increase accuracy
and reproducibility (19). These include:
(1) Boundaries between lower uterine segment and
upper endocervix are poorly deﬁned.
(2) Florid reactive changes within endocervical glands
may mimic secondary involvement by EC.
(3) Tumor may be superﬁcially implanted within
cervical surface epithelium, sometimes in associa-
tion with granulation tissue related to prior
endometrial sampling.
(4) Distinction of endocervical gland involvement
from stromal invasion may be challenging and
FIGO has not provided working deﬁnitions to
distinguish gland from stromal involvement.
(5) Some well-differentiated endometrioid ECs are
not accompanied by a stromal response when
inﬁltrating the cervix (38).
Practice-based suggestions have been provided by the
working group on how to recognize cervical stromal
invasion. Cervical stromal invasion can be identiﬁed by
the presence of a desmoplastic stromal response, and/or
loss of the “normal” architectural arrangement of
neoplastic glands in comparison to preexisting endocer-
vical glands. In the latter scenario, the normal
architecture of glands in uninvolved areas of endocervix
should be utilized to assess preexisting endocervical
architecture. Although no clear boundary exists, it is
suggested that the uppermost mucinous endocervical
gland be taken as the boundary between the LUS and
endocervix but this may be challenging, as this area not
infrequently has alternating mucinous and inactive/
ciliated LUS glands. It is also recommended that
endocervical stromal involvement be diagnosed when
tumor shows a conﬂuent growth within the cervix or
neoplastic glands are noted in between preexisting
endocervical glands (19) (Fig. 3).
In addition to identifying the presence of cervical
stromal invasion, depth of invasion within the cervical
wall should be reported (1). It may be a measurement
in millimeters from the surface compared with the
thickness of the cervical wall or as an indication of the
proportion of the thickness of the cervical wall. In
cases showing cervical stromal inﬁltration, the margin
status should be reported as positive or negative (with
minimum distance), for both the radial/outer cervical
and distal margins (16,39).
Uterine Serosal Involvement
Recommendations:
 Presence or absence of uterine serosal involvement
should be recorded as its presence upstages an EC
to stage IIIA.
FIG. 3. Cervical stromal involvement should be diagnosed when
tumor shows confluent growth within the cervix or neoplastic
glands are noted adjacent to preexisting endocervical glands.
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 Tumor inﬁltrating the full myometrial thickness
and reaching submesothelial ﬁbroconnective tissue
or the mesothelial layer should be reported as
serosal involvement; tumor may or may not be
present on the surface of the uterus; a desmoplastic
response may or may not be present.
There is essentially no information in the literature
pertaining to the recognition of this parameter. For
colorectal cancers, serosal involvement has been
deﬁned as “transgression of the serosal surface (i.e.
mesothelial layer) by malignant cells” (40). The
deﬁnition utilized for colorectal cancers may not
apply to uterine cancers since the serosal layer
investing the uterus is thin, consisting only of very
scant ﬁbroconnective tissue and mesothelium over-
lying a distinct and regular outer myometrial border,
and there is no deﬁned “subserosal” layer of adipose
and ﬁbroconnective tissue. As inﬁltrating ECs often
elicit a desmoplastic response, tumor involving the
serosa may be associated with collagenous stroma and
the mesothelial layer may be imperceptible (as occurs
frequently). Thus, the presence of tumor on the
serosal surface may be obvious in most instances
(Fig. 4), but sometimes difﬁcult to recognize, even
when multiple levels are examined. Uterine serosal
involvement should therefore be deﬁned as tumor
inﬁltrating through the entire thickness of the
myometrium and reaching the ﬁbroconnective tissue
or mesothelium, regardless of whether this appears to be
exposed or not (Fig. 5). This is often associated with
pallor, dullness, or discoloration of the outer uterine
surface on gross examination and such areas should
be submitted for histologic examination. Of note, the
presence of lymphovascular space involvement within
the serosa should not be considered as true serosal
involvement or stage IIIA.
Adnexal Involvement
Recommendations:
 The presence or absence of adnexal involvement
should be recorded as its presence upstages an EC
to stage IIIA.
 Care should be taken to determine whether the
adnexal involvement is considered to be metastatic
or “synchronous.”
 Type of adnexal involvement (ovarian parenchy-
ma/surface, tubal mucosa/wall, paraadnexal tissue,
or lymphovascular space involvement) should be
recorded.
 The presence of lymphovascular space involvement
only at any adnexal site does not affect stage.
Detailed histologic studies of the adnexal tissues in
recent years have revealed that the issue of adnexal
involvement by EC is more complicated than
previously realized. ECs involving the adnexa are
categorized as stage IIIA, and patients have an overall
survival rate of ∼75%. This scenario has to be
distinguished from synchronous primary tumors in
the endometrium and the ovary or tube, that often are
associated with an indolent outcome (41). To further
complicate matters, recent studies have demonstrated
a clonal relationship between some of these so-called
independent synchronous tumors, especially endome-FIG. 4. Tumor involving uterine serosal surface.
FIG. 5. Serosal involvement may be accompanied by a desmo-
plastic and inflammatory reaction; the presence of tumor cells on
the outer surface may not be obvious in individual sections. When
tumor infiltrates the full myometrial thickness and involves the
submesothelial fibroconnective tissue, this should be taken as
evidence of serosal involvement.
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trioid carcinomas (42,43). For these reasons, accurate
classiﬁcation of an adnexal neoplasm in a woman
with endometrioid EC as metastatic versus synchro-
nous may be a difﬁcult task for the pathologist. The
distinction between so-called synchronous independ-
ent adnexal and ECs and metastatic disease from one
site to the other is discussed in more detail in another
review in this issue (44).
Fallopian Tube Involvement—Recommendations:
 The presence of detached tumor cells in the tubal
lumen should be reported, but this ﬁnding per se
does not upstage EC.
 Tubal intraepithelial (mucosal) carcinoma, with or
without stromal invasion, should, in the setting of a
tumor within the endometrium, be viewed as meta-
stasis from the EC, which should be upstaged due to
tubal involvement.
 In cases of high-grade serous carcinoma, ancil-
lary techniques should be undertaken to help
deﬁne the primary site.
 In cases of endometrioid EC a comment may be
included on the unknown prognostic signiﬁcance
of this ﬁnding.
 Carcinomas metastatic to the wall of the fallopian
tube and/or its serosa are viewed as metastatic from
the endometrium, unless an origin in endometriosis
is found, and the EC is accordingly upstaged.
Fallopian tube involvement in EC can have multiple
possible sites/patterns. The following scenarios may be
encountered:
(1) Fragments of tumor or aggregates of tumor cells
within the tubal lumen, with no involvement of the
mucosa, wall, or serosa. In current practice, frag-
ments of tumor and tumor cell aggregates are not
uncommonly observed in the tubal lumen, mainly in
patients operated on using techniques that involve
an intrauterine manipulator, such as a laparoscopi-
cally assisted or robotic hysterectomy (45,46). So far,
it has not been shown that these free-ﬂoating tumor
fragments are associated with an adverse outcome;
they are generally noted in the pathology report, but
are not viewed as tubal involvement indicative of
stage IIIA disease. This statement pertains to
endometrioid EC, but the situation may be different
if the EC is of serous type. Snyder et al. (47) reported
that the presence of serous tumor cells in the tubal
lumen was often associated with peritoneal meta-
stases. Interestingly, it has been recently reported
that patients with aggressive forms of EC such as
serous carcinoma were likely to have lower stage
disease and lower mortality if they had a prior tubal
ligation, which would obstruct transtubal spread of
tumor (48,49). Thus, it is particularly important to
note the presence of intratubal tumor cells in serous
carcinoma and other types of high-grade EC,
although there is currently no consensus to upstage
these EC based only on the presence of tumor cells
within the fallopian tube lumen.
(2) Involvement of tubal mucosa only with a pattern of
growth that raises the question of intraepithelial
carcinoma. Even though an intraepithelial carci-
noma might be viewed as evidence of a primary
process, it has been shown that metastatic
carcinomas in the fallopian tube can show intra-
epithelial growth that mimics a primary intra-
epithelial carcinoma (50,51). Factors such as prior
tubal ligation, site of tubal involvement, patterns
of WT1, p53, and p16 immunohistochemistry in
serous carcinomas and molecular studies may
permit a more accurate determination of whether
an intraepithelial carcinoma in the fallopian tube
represents the primary site or, in rare cases, a
synchronous primary (52,53). The distinction
between so-called synchronous independent tubal
and ECs and metastatic disease from 1 site to the
other is discussed in more detail in another review
in this issue (44).
(3) Involvement of mucosa and deeper layers of the
fallopian tube wall, raising the differential diagnosis
of synchronous primary tubal carcinoma versus
metastasis. The same principles as described above
for intraepithelial involvement are used to deter-
mine the relationship between the neoplasms. It
should be noted that detailed sampling of the
fallopian tube, as has become commonplace in
recent years, may result in increased detection of
tubal mucosal spread in low-grade endometrioid
EC, the prognostic signiﬁcance of which is
currently uncertain.
(4) Involvement of deep layers of the fallopian tube
wall, often with tumor in lymphovascular spaces,
with no mucosal involvement. This is indicative of
metastatic EC. A tubal carcinoma cannot be a
synchronous primary tumor without a component
that involves the tubal mucosa (including intra-
epithelial), so if the carcinoma is limited to the
deeper layers of the fallopian tube wall or serosa,
it is metastatic. The 1 exception to this rule could
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be a carcinoma that has arisen in tubal endome-
triosis but this is an extremely rare scenario.
LVSI can be seen in both primary and metastatic
tubal tumors, but its presence should always result in the
pathologist considering the possibility of metastasis.
Occasionally, the only site of tubal involvement by a
metastatic EC is within tubal lymphovascular spaces; an
entirely intravascular carcinoma is certainly metastatic
to the tube, but does not upstage the primary tumor.
The prognostic signiﬁcance of this ﬁnding has not been
adequately studied.
Ovarian Involvement—Recommendations:
 Ovarian metastases in patients with EC should be
categorized as stage IIIA.
 Ovarian carcinomas that are low-grade endome-
trioid in type and do not show features suggestive
of metastasis, can be considered for staging and
management as synchronous primary low-stage
neoplasms, especially if associated with endome-
triosis. Such cases may be discussed at tumor
board/multidisciplinary meetings.
 In the case of high-grade serous carcinoma involv-
ing the endometrium and ovary, most are ovarian
tumors metastatic from the endometrial primary
and this should result in tumor upstaging.
 In the extremely rare scenario where the ovarian
tumor, if serous, is viewed as separate from the
endometrial tumor based on immunohistochemical
or molecular studies, it is important that the
fallopian tubes be completely evaluated using the
SEE-FIM protocol to exclude a tubal primary site.
The ﬁnding of tumor in the endometrium and ovary
raises the differential diagnosis of synchronous primary
tumors versus a metastasis, usually from the endome-
trium to the ovary. The distinction between so-called
synchronous independent ovarian and ECs and meta-
static disease from 1 site to the other is discussed in more
detail in another review in this issue (44).
Involvement of Other Adnexal Sites, Such as
Periadnexal Soft Tissue and Broad Ligament—
Recommendation:
 Unless an obvious source for a primary carcinoma
is identiﬁed, carcinomas in this region should be
considered metastatic and the EC upstaged to IIIA.
Metastatic EC involving adnexal sites other than the
ovary or fallopian tube has not been well studied. It is
uncommon as an isolated ﬁnding, and when detected
tends to occur in patients with tumor involvement of the
fallopian tube or ovary. Pathologists always need to
keep in mind that the same types of carcinoma that
occur in the endometrium can rarely arise in the
periadnexal soft tissue and broad ligament, from
endometriosis, endosalpingiosis, or from benign tumors
that occur at these sites, so the possibility of synchro-
nous neoplasms does exist, although this is rare.
Parametrial Invasion
Recommendations:
 Presence or absence of parametrial invasion should
be recorded as its presence upstages an EC to
stage IIIB.
 The ﬁbroconnective tissue around the isthmus, at
the cervix/lower uterine segment junction should be
regarded as part of the parametria.
 Parametrial spread may be in direct continuity with
the primary tumor (continuous spread), or may be
identiﬁed as discrete metastases, in lymphovascular
spaces, or in LNs (discontinuous spread).
 Continuous spread or discrete metastases into or in
the parametrial tissue is required for diagnosis of
parametrial involvement and staging of an EC
as IIIB.
The parametria are composed of ﬁbroconnective
tissue, which surrounds the supravaginal part of the
cervix and separates this part of the cervix anteriorly
from the bladder and posteriorly from the rectum.
This parametrial tissue extends onto the sides of the
supravaginal cervix and between the layers of the
broad ligaments (16). LNs, uterine blood vessels, and
lymphatics that supply and drain the cervix are
contained within the parametrial tissue. The ureters
course downward and forward through the para-
metria on both sides of the cervix.
Radical hysterectomy includes a bilateral para-
metrectomy; this is generally performed for the
treatment of cervical carcinoma and may be under-
taken for ECs that arise in the lower uterine segment
and/or secondarily extend to the cervix, in order to
obtain clear surgical margins (2,19,54). Although a
simple hysterectomy specimen, usually performed for
ECs, includes minimal parametrial tissue, a small
amount of ﬁbrovascular connective tissue is usually
attached (55) as the paracorpus and paracervix. Some
pathologists embed the soft-tissue shavings from these
areas and record whether they contain tumor or show
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LVSI but this is not uniform practice, nor is it
evidence based.
Parametrial involvement by EC may be continuous
or discontinuous from the main tumor. Discontinuous
parametrial involvement may be seen as metastasis to
LN, tumor within lymphovascular spaces, or as
discrete metastatic deposits. Discontinuous inﬁltration
of the parametrial soft tissue (19) as a result of
outgrowth of tumor from foci of lymphovascular
invasion is very rare. Parametrial involvement by EC
typically occurs by direct extension of a deeply
myoinvasive tumor or via LVSI. In either scenario,
tumor carryover in the parametrium should be highly
suspected in an EC without deep myometrial invasion
or LVSI.
Stromal inﬁltration by EC is required to fulﬁll the
criteria of parametrial involvement and thereby FIGO
stage IIIB. The presence of tumor in lymphovascular
spaces should be noted but does not upstage to stage
IIIB; similarly the presence of parametrial LN
involvement contributes to the overall LN staging,
but does not constitute parametrial involvement.
Continuous and discontinuous parametrial stromal
inﬁltration are both staged as FIGO IIIB. Although
the long-term prognosis is signiﬁcantly poorer for
endometrial cancer patients with parametrial spread,
multivariate analysis at least in some studies has
shown this parameter not to be an independent
prognostic factor in EC (56).
Vaginal Involvement
Recommendations:
 Presence or absence of vaginal involvement should
be recorded where vaginal tissue is included in the
resection specimen or submitted separately, as its
presence upstages an EC to stage IIIB.
 The term “drop-metastasis” should not be used in
surgical pathology reports, as it is nonspeciﬁc.
 Identiﬁcation of any true involvement by EC
(i.e. nonﬂoater), regardless of size, should be
reported.
Vaginal involvement is currently deﬁned in staging
systems as present/absent (15), and the pattern of
involvement is not further described. Vaginal involve-
ment can be in the form of direct extension or “drop-
metastasis,” the latter deﬁned as tumor involvement
without direct communication to the dominant mass
and believed to arise from tumor seeding possibly as a
result of surgical intervention. There is no minimum
size criterion for vaginal involvement (whether
considered to be direct extension or drop-metastasis).
Similarly, the location of the metastasis (upper,
middle, or lower third of vagina) plays no role in
staging and does not appear to have an effect on
patient outcome.
LN Involvement (Nonsentinel)
Recommendations:
 Presence or absence of lymph nodal metastasis
> 0.2 mm in size should be recorded where LN are
included as part of the resection as its presence
upstages an EC to stage IIIC.
 Slicing of LN at 2 to 3 mm intervals along an axis
perpendicular to the longest axis for histologic
processing is preferable to bisecting nodes. If
sectioned in this way, additional levels are not
routinely recommended.
 The number of involved nodes and the total
number of nodes retrieved from each site should
be provided in the pathology report; in formal LN
dissections, this may be expressed as the lymph
node ratio (LNR) if this is the local reporting
protocol.
 On the basis of limited evidence, the pattern of LN
metastases and the presence of extracapsular spread
should be reported.
 Size of metastatic nodal deposits may be docu-
mented in pathology reports.
 According to TNM 8, the presence of isolated
tumor cells (ITCs) deﬁned as metastatic disease
<0.2 mm or pN0(i+) does not upstage an EC (14).
Nodal involvement is one of the most powerful
prognostic determinants in all cancers, and predicts
distant recurrence in low-risk EC (37). Pelvic (including
parametrial) node involvement is FIGO stage IIIC1
and paraaortic nodal involvement stage IIIC2. The
presence of positive nodes identiﬁes a high-risk
population and helps to tailor adjuvant treatment
(57). However, at the same time, systematic pelvic
(+/− paraaortic) nodal dissection, which is associated
with signiﬁcant morbidity, has not demonstrated any
overall survival beneﬁt (58,59), and thus practices vary
worldwide. While in North America, there has been a
high frequency of systematic node dissection, the extent
to which routine lymphadenectomy is undertaken in the
rest of the world varies considerably. It is important for
standard and uniform protocols to be followed in LN
sampling and reporting.
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A further issue is the increased morbidity of nodal
dissection carried out as a second procedure (60),
which has prompted evaluation of intraoperative
assessment and complete dissection as a single
procedure; this is likely to vary with local practices,
but, if offered, frozen section shows improved
accuracy over imprint cytology for the detection of
macrometastases, while both procedures miss micro-
metastases at the same frequency (61).
The major lymphatic trunks draining the uterus are
uteroovarian (infundibulopelvic), parametrial, and
presacral trunks, which drain into the hypogastric,
external iliac, common iliac, presacral, and paraaortic
nodes (62). To date, recommendations regarding LN
counts in EC have not been reﬂective of the probability
of ﬁnding disease. The Gynecologic Oncology Group
Surgical Procedures Manual suggests that a minimum
of 10 LNs be retrieved for evaluation. This is based on
their recommendation that at least 1 LN be removed
from each node-bearing region in the pelvis and
paraaortic area (62,63). Recently, several studies have
directly or indirectly examined the relationship between
LN counts and the probability of ﬁnding nodal
metastases in EC. Two retrospective reviews found
that patients had improved survival when at least 10 to
12 LN were removed during lymphadenectomy. The
improved survival was possibly due to adjuvant
treatment following stage migration (better identiﬁca-
tion of patients with stage IIIC). Of note, paraaortic
nodes may be positive in the absence of pelvic LN
involvement in 9% of cases (64–66).
Study of deeper sections of conventional (non-
sentinel) LNs has no value provided the LNs are
sectioned at 2 to 3 mm intervals along an axis
perpendicular to the longest axis (bread-sliced) rather
than bisected (67), ideally with no > 3 pieces per tissue
cassette, as bisection presents less of the LN cross-
sectional area than bread-slicing.
There are limited studies that correlate size/pattern
of metastatic deposits in LNs with prognosis in EC.
The ratio of positive to negative LNs or LNR has
been investigated with a reduced progression-free
survival in patients who had at least 10 LNs removed,
and who had a LNR > 50% compared with patients
who had LNR ≤ 50% (68). A retrospective review of
612 surgically staged EC patients speciﬁcally looking
at patterns of pelvic nodal involvement found that
distant and paraaortic nodal recurrence was associ-
ated with extracapsular pelvic nodal disease as well as
with metastases with a diameter > 2mm (69). A
separate study also found the number of positive LN,
desmoplasia in LNs, and extension of carcinoma into
perinodal adipose tissue to be the most important
adverse prognostic factors in stage IIIC EC (63).
Sentinel LN Ultrastaging
Recommendations:
 Sentinel LNs may undergo ultrastaging by a
protocol that includes examination of deeper levels
+/− immunohistochemistry in addition to an initial
hemotoxylin and eosin (H&E) section if this is
negative for metastasis.
 Micrometastasis (deﬁned as a focus of metastatic
disease 0.2–2 mm in maximum diameter) and ITCs
(deﬁned as metastatic disease <0.2 mm) should be
documented in the surgical pathology report,
though the prognostic signiﬁcance of these ﬁndings
is unclear at present.
 Presence of ITCs does not upstage an EC (14).
Most ECs are conﬁned to the uterus (FIGO stage I)
and have 5-yr overall survival rates of 80% to 90%.
However, about 10% to 15% of these patients will, in
fact, have metastatic nodal disease, of whom nearly
15% have grade 1 endometrioid EC on preoperative
biopsy; therefore, it is important to stage and treat
these patients properly and avoid missing undetected
metastatic disease.
Sentinel LN assessment is a useful option for these
patients. For this reason sentinel node procedures
have been evaluated in large series as well as
randomized trial settings following breast cancer
protocols, as an alternative to systematic node
dissection (70–72). Sentinel node removal has been
shown to be a safe alternative to LN dissection and
long-term outcomes are now being reported with
potential for development of optimal protocols in the
near future (72,73). Sentinel node examination with
ultrastaging may upstage low-risk and intermediate-
risk EC (71), as well as high-risk EC (74). The
presence of macrometastases (> 2 mm) predicts in-
volvement of nonsentinel nodes in EC, and is
associated with worse outcome in comparison with
node-negative EC (75). The long-term signiﬁcance of
ITCs (o0.2 mm) and micrometastases (0.2–2 mm)
remains uncertain, as patients showing this very
limited LN involvement have no signiﬁcant differ-
ences in survival from patients with node-negative
EC; this may be because these cases have often been
treated as stage IIIC disease and have been given
adjuvant therapy (70,72,73). Ultrastaging utilizing
serial sections and cytokeratin stains improves
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detection of metastasis in individual studies, though
this has not been conﬁrmed in a recent metaanalysis
(76). The above studies, that have reported long-term
outcomes of low volume nodal metastases, state that
further research is needed.
Several different protocols have been published for
sentinel node ultrastaging, and all perform compara-
bly with regard to detection of metastasis (70,77).
Comparison of a comprehensive ultrastaging protocol
with a simpler one showed that there was no
statistically signiﬁcant difference with respect to
number of positive sentinel nodes detected, size of
metastasis or false-negative rate (77). The presence of
ITC does not upstage EC (TNM 8) (14).
Micrometastasis (deﬁned as a focus of metastatic
disease 0.2–2 mm in maximum diameter) and ITCs
(deﬁned as metastatic disease <0.2 mm) should be
documented in the surgical pathology report, though
the prognostic signiﬁcance of these ﬁndings is unclear
at present.
Confounding factors in the evaluation of metastases
are the presence of mesothelial cells or benign
epithelial inclusions (endosalpingiosis, endometriosis)
within nodes. If mesothelial cells are suspected,
staining for a mesothelial marker such as calretinin
may be of value. Epithelial inclusion glands are
typically seen within the LN capsule or septa and if
necessary ﬁndings on immunostained slides should be
correlated with H&E appearances.
LVSI
Recommendations:
 Presence or absence of LVSI should be recorded in
the pathology report.
 The sites of LVSI should be recorded.
 Before diagnosing LVSI, mimics should be excluded,
such as retraction, MELF pattern of invasion, and
artifactual displacement of tumor cells
 Immunohistochemistry is of limited use in the
identiﬁcation of LVSI.
 When present, LVSI should be reported as the
number of vessels involved or semiquantiﬁed as
“focal” or “substantial/extensive”.
LVSI is deﬁned as the presence of viable tumor
within endothelium-lined spaces, typically as clusters
of cells that appear “free-ﬂoating” and often conform
to the shape of the space (Fig. 6). The presence of
associated proteinaceous material is helpful in
recognition as a lymphatic space. In some studies,
t-
he ﬁnding of perivascular lymphocytic inﬁltrates has
been shown to be associated with LVSI, but this
ﬁnding is not diagnostic, and the presence of actual
tumor emboli within the vessels is required for a
diagnosis of LVSI (78,79).
The extent of LVSI is a prognostic factor. Involvement
of more myometrial vessels, and vessels distant from the
invasive front of the tumor predict LN metastasis and
survival (80). Conversely LVSI conﬁned to rare vessels
involved at the invading front are of questionable
prognostic value and classiﬁed by some pathologists as
“indeterminate,” corresponding to the deﬁnition of
“focal” below. A pooled analysis from 2 large clinical
trials which included specialist review of 926 endome-
trioid EC for the presence of LVSI and evaluation of
2-tier, 3-tier, and 4-tier grading systems for LVSI has
reported that: (a) the incidence of LVSI is low in stage
I endometrioid EC (13.9% in this study); and (b)
“substantial” LVSI, as opposed to “no” or “focal”
LVSI, is the strongest independent prognostic factor for
pelvic regional recurrence, distant recurrence, and overall
survival (81). The deﬁnition of “substantial” in this study
as the presence of ≥3 distinct, that is, widely separated
vessels, is broadly in agreement with that of a consensus
among gynecologic pathologists from different institu-
tions, as absent, low (o3 vessel involvement), or
extensive (≥3 vessels involved) (78). While of uncertain
signiﬁcance, it is suggested that the location (eg, deep
myometrial, cervical, adnexal, parametrial, etc.) of LVSI
be documented in the pathology report to allow for
future studies to assess for possible signiﬁcance.
Tumor cells can be displaced into vascular spaces
during processing or uterine manipulation. Features
of intravascular tumor morphology associated with
FIG. 6. Lymphovascular space invasion in endometrial carcinoma.
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so-called “vascular pseudoinvasion” include associ-
ated necroinﬂammatory debris or benign endome-
trial glands, or disaggregated tumor cells (79).
Another artifact is the presence of tumor cells
lodged in artifactual tissue clefts of the myome-
trium, which suggests a fragile tumor prone to
displacement (45). Cases with these features should
be evaluated carefully to distinguish between true
LVSI and “vascular pseudoinvasion” and the 2 may
coexist. In some cases, the distinction may be
impossible and such cases should be classiﬁed as
“indeterminate.” As the incidence of LVSI is low in
low-stage endometrioid EC, an effort should be
made to distinguish true LVSI from such mimics
(79). Immunohistochemistry is of limited value in
this distinction and reliance should be placed on the
H&E appearance (82,83).
Prognostic Factors Unrelated to Stage and With
Limited/Conflicting Supporting Evidence
Recommendations:
 Tumor size should be included in the pathology
report; this may be derived from macroscopic or, in
the case of very small tumors, histologic assessment,
or a combination.
 Tumor location may be included. In particular
tumors located in the LUS region should be
carefully evaluated as these may require distinction
between an endocervical and an endometrial origin.
Lower uterine segment ECs may be associated with
Lynch Syndrome (84).
 Measurement of absolute depth of myometrial
invasion, percentage of myometrium inﬁltrated by
tumor, invasion of inner, middle, or outer one third
of the myometrium, distance of myoinvasive tumor
to serosal surface: any of these measurements may
be carried out and included in the report according
to local preference.
 Presence of a MELF pattern of myometrial invasion
and presence or absence of histiocyte-like malignant
cells may be recorded; although its prognostic
signiﬁcance has not been consistently demonstrated,
the presence of this pattern of invasion warrants
careful assessment of LVSI and avoidance of under-
estimation of myoinvasive depth.
 Peritoneal cytology is no longer necessary for
staging but positive cytology should be recorded.
Tumor size is reported to predict LN involvement
and recurrence and thereby can be utilized during
preoperative or intraoperative assessment to determine
the need for nodal dissection (37,85). Recording of
tumor size is currently optional and is included in
most reporting data sets as a noncore item, however,
in incompletely staged apparent low-stage tumors,
tumor size inﬂuences the recommendation for adjuvant
therapy (1).
Tumor location within the uterine corpus may
have clinical signiﬁcance and should be recorded as
LUS, body, fundus, or cornu. Approximately 14%
of ECs arise in the lower uterine segment and these
are more frequently associated with mismatch repair
gene abnormalities and Lynch Syndrome. Lower
uterine segment involvement has also been shown to
be an independent prognostic factor in conferring a
higher risk of distant recurrence and death (84,86).
Furthermore, when a tumor involves the lower uterine
segment without a tumor mass in the corpus, it is
important to distinguish between a cervical and an
endometrial origin, as this has important management
implications (this distinction is discussed in more
detail in another review in this issue (44)).
Measurement of absolute depth of myometrial
invasion, invasion of inner, middle, or outer one third
of the myometrium, percentage of myometrium inﬁl-
trated by tumor, distance of myoinvasive tumor to
serosal surface. These related absolute measurements
(in mm) have been studied and not found to be
consistently and independently predictive of progno-
sis. These do not add to the categorical assessment of
inner half versus half or more of myometrial thickness
involvement, which is also integral to tumor staging.
Any of these may be included in the report but are
currently optional and included in most reporting
data sets as noncore items.
MELF pattern of myometrial invasion is reported
to correlate with lymph nodal metastasis (87,88). In
addition to conventional expansile and inﬁltrative
patterns of myometrial invasion (89), rarer patterns of
invasion may occur in endometrioid EC. These
include an adenoma malignum-like pattern and
MELF-type invasion. The latter is characterized by
a prominent ﬁbromyxoid desmoplastic stromal reac-
tion, with a subset showing outpouchings and
detached glands which are dilated and lined by
ﬂattened epithelium creating microcysts. There may
also be gland elongation or fragmentation resulting
in small solid clusters of cells or single cells. This
pattern of myoinvasion shows immunohistochemical
features in tumor cells suggesting that the phenotypic
changes are related to the phenomenon of “epithelial-
mesenchymal transition” (30,90). A MELF pattern of
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invasion is reported to be associated with a higher
likelihood of nodal involvement and distant recur-
rence but its signiﬁcance as an independent risk factor
remains unclear (91,92), possibly partly related to a
level of subjectivity in its recognition.
Therefore, the presence of MELF-pattern invasion
does not currently inﬂuence patient management but
together with other invasive patterns remains the
focus of research studies. Nevertheless, the recogni-
tion and recording of this parameter is important for
other reasons. First, this is a subtle pattern often seen
focally at the invasive front in tumors that are low
grade (Fig. 7). Because of the relative pallor and
different appearance of the tumor at these sites, it may
be missed, resulting in underestimation of depth of
invasion. Second, this is typically seen as glands with a
markedly attenuated lining showing detached tumor
cells within the lumen, ﬁndings that may be wrongly
interpreted as LVSI. Third, this pattern is signiﬁcantly
associated with LVSI, and when present a careful
search should be performed to exclude as well as
correctly identify LVSI, which is otherwise an
uncommon ﬁnding in low-grade endometrioid EC.
Fourth, the presence of MELF-pattern invasion will
prompt histopathologic ultrastaging of resected LNs for
occult metastatic involvement within some institutions.
Finally, as discussed above in the section on “myometrial
invasion,” the depth of invasion in this and other ECs
with a ﬁbromyxoid stromal reaction, should be based on
the ﬁnding of neoplastic epithelial cells, and not the
reactive stroma (Fig. 8).
Peritoneal Cytology
Positive peritoneal cytology is no longer included in
staging of EC but is recommended as part of the
surgical procedure (1) (National Comprehensive Cancer
Network). There is lack of consensus in the literature
regarding its prognostic signiﬁcance in the absence of
other evidence of extrauterine spread. A recommenda-
tion has been made by FIGO and the Union for
International Cancer Control to record the status of
peritoneal washings if these have been carried out,
without altering the tumor stage, if these are positive for
malignant cells (15), as this is taken to be an adverse
risk factor when considering adjuvant therapy (1).
CONCLUSIONS
A number of factors related to and independent of
tumor stage help to determine the need for adjuvant
therapies in patients with EC. The accurate and
consistent reporting of these pathologic parameters is
vital to ensure optimal patient management.
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